Deals In Depth: August 2016
Executive Summary
Pfizer signed multiple billion-dollar deals, including buying AstraZeneca's anti-infectives portfolio for $1.6 billion and acquiring Medivation – and the blockbuster cancer drug Xtandi – for $14 billion. Follow-on public offerings accounted for 52% of both biopharma and device financing.
You may also be interested in...
RNA Medicines: Advancements Leading To Investments
Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.
The Biopharma A List: Taking The Pulse Of Newco Creation
The market for new company creation in the biopharma sector remains healthy and poised to continue fostering the establishment of start-ups, based on a new In Vivo study of the strong initial investments that pharma and biotech companies receive.
Seven Key Success Factors In Market Opportunity Assessments
In conducting pharma market opportunity assessments, there are several best practices that exist and common mistakes to avoid. In Vivo shares expert learnings from Pharma Intelligence’s Custom Intelligence leaders.